R-Doxazosin D8

Thermal analysis study of antihypertensive drug doxazosin mesilate
Ali K.AttiaMona M.Abdel-MoetySamar G.Abdel-Hamid
Arabian Journal of Chemistry Volume 10, Supplement 1, February 2017, Pages S334-S338
 
Separation, Characterization, and Quantitation of Process-Related Substances of the Anti-Hypertensive Drug Doxazosin Mesylate by Reversed-Phase LC with PDA and ESI-MS as Detectors
R. Nageswara Rao1,*, D. Nagaraju1, A.K. Das2, and Nivedita Jena
J Chromatogr Sci. 2007 Feb;45(2):63-9.
 
Validation and pharmacokinetic application of a method for determination of doxazosin in human plasma by high-performance liquid chromatography
Pattana Sripalakit,1,2* Penporn Nermhom2 and Aurasorn Saraphanchotiwitthaya3
Biomedical chromatography biomed. chromatogr. 20: 729–735 (2006)

R-Doxazosin D8 is chemically (R)-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl-2,2,3,3,5,5,6,6-d8)(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanone. R-Doxazosin D8 is supplied with detailed characterization data compliant with regulatory guideline. R-Doxazosin D8 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Doxazosin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.